Biotechnology - Financial

Filter

Current filters:

Financial

Popular Filters

1 to 25 of 440 results

Royalty Pharma pays $3.3 billion for CFF royalty rights to Kalydeco

19-11-2014

Royalty Pharma says it has acquired royalties on Vertex Pharmaceuticals' cystic fibrosis treatments,…

BiotechnologyFinancialKalydecoRare diseasesRoyalty PharmaVertex Pharmaceuticals

Onxeo receives $25M milestone payment from Spectrum on Beleodaq

14-11-2014

Onxeo, created by a merger between French company BioAlliance Pharma, and Danish biopharmaceutical company…

BeleodaqBiotechnologyFinancialHematologyLicensingOncologyOnxeoSpectrum PharmaceuticalsUSA

Increased scrutiny by EU5 health authorities will encourage off-label use of Avastin for wet-AMD

06-11-2014

Cost-constrained health authorities in the EU5 (France, Germany, Italy, Spain, and the UK) are increasingly…

AvastinBiosimilarsBiotechnologyEuropeFinancialLucentisMarkets & MarketingNovartisOphthalmicsRoche

Genmab reports nine month interim results, including $31 million revenue increase on 2013

Genmab reports nine month interim results, including $31 million revenue increase on 2013

06-11-2014

Danish biotech company Genmab has reported its nine-month interim results, including an increase in revenue…

BiotechnologydaratumumabDenmarkDuoBodyFinancialGenmabOfatumumab Injection

Regeneron third-qtr net profit plunges despite strong sales growth

Regeneron third-qtr net profit plunges despite strong sales growth

04-11-2014

US biotech firm Regeneron posted revenue of $725.8 million for the third quarter of 2014, a rise of 22%…

alirocumabBayerBiotechnologydupilumabEyleaFinancialOphthalmicsRegeneronResearchSanofisarilumab

Pharming strengthens balance sheet with $20 million milestone from Salix

Pharming strengthens balance sheet with $20 million milestone from Salix

04-11-2014

Dutch biotech company Pharming Group says it has received a $20 million milestone payment from the USA’s…

BiotechnologyFinancialPharming GroupRare diseasesRuconestSalix Pharmaceuticals

Celladon links with Lonza for commercial manufacturing of Mydicar

03-11-2014

Swiss chemical supplier Lonza and US biotech firm Celladon Corp have entered into an agreement providing…

BiotechnologyCardio-vascularCelladonFinancialLonzaProduction

Affinivax launches, aiming to develop novel conjugate vaccine

30-10-2014

Affinivax, a US biotechnology company dedicated to developing novel vaccines, today announced its launch…

AffinivaxBiotechnologyFinancialResearchVaccines

Gilead third-qtr sales beat expectations, but Sovaldi disappoints

Gilead third-qtr sales beat expectations, but Sovaldi disappoints

29-10-2014

There was mixed news late yesterday from US anti-virals major Gilead Sciences, when the biotech posted…

Anti-viralsBiotechnologyFinancialGilead SciencesHarvoniSovaldiUSA

Ferrer buys $8 million of Alexza shares, to eliminate certain Adasuve milestone payments

Ferrer buys $8 million of Alexza shares, to eliminate certain Adasuve milestone payments

28-10-2014

US drugmaker Alexza Pharmaceuticals and privately-held Spanish firm Grupo Ferrer Internacional have amended…

AdasuveAlexza PharmaceuticalBiotechnologyFerrer InternacionalFinancialLicensingNeurologicalUSA

Licensing deal index shows re-emergence of late-stage deals

Licensing deal index shows re-emergence of late-stage deals

28-10-2014

Licensing deals among biotech companies have recently shown a healthy surge, especially in later stages.

BiotechnologyCelgene Corp.FinancialLicensingMorrisonUK

Despite restructuring costs, Amgen’s third-qtr beats expectations

Despite restructuring costs, Amgen’s third-qtr beats expectations

28-10-2014

US biotech major Amgen posted a fall in earnings for the third-quarter of 2014, due to restructuring,…

AmgenBiotechnologyFinancialThousand Oaks, CaliforniaUSA

Celgene third-quarter results beat estimates; ups guidance

Celgene third-quarter results beat estimates; ups guidance

23-10-2014

US biotech major Celgene today reported better-than-expected financial results, with net product sales…

BiotechnologyCelgene Corp.Celgene Corp.FinancialUnited StatesUSA

Biogen Idec third-qtr net rockets 76% but shares slump

Biogen Idec third-qtr net rockets 76% but shares slump

23-10-2014

US biotech firm Biogen Idec saw its share price plunge 7% to $303.51, after its posted third-quarter…

Biogen IdecBiotechnologyFinancialNeurologicalTecfideraUSA

Amgen advised to consider ‘radical’ split by lead investor

Amgen advised to consider ‘radical’ split by lead investor

22-10-2014

One of Amgen’s largest shareholders has said the USA-based biotechnolgy comapny would be better off…

AmgenBiotechnologyFinancialThousand Oaks, CaliforniaUK

Actelion beats expectations as third-qtr net profit rockets 39%

Actelion beats expectations as third-qtr net profit rockets 39%

21-10-2014

Switzerland’s Actelion, Europe’s largest biotech company, this morning announced third-quarter 2014…

ActelionBiotechnologyFinancialOpsumitRespiratory and PulmonarySwitzerlandTracleer

Profectus BioSciences gets US government funding for Ebola vaccine development

17-10-2014

Under a one-year contract with US biotech firm Profectus BioSciences, the US Department of Health and…

Anti-viralsBiotechnologyFinancialProfectus BioSciencesResearchUSA

Biotherapies could save millions of euros when treating auto-immune diseases

Biotherapies could save millions of euros when treating auto-immune diseases

08-10-2014

Health care providers could save millions of euros if biotherapies were used in the treatment of Crohn’s…

Anti-Arthritics/RheumaticsBiotechnologyEuropeFinancialHealthcareResearchTheradiag

Incyte earns $60 million milestone on European reimbursement for Jakavi

Incyte earns $60 million milestone on European reimbursement for Jakavi

02-10-2014

US biopharma company Incyte says that it has earned a $60 million milestone payment from Swiss pharma…

BiotechnologyEuropeFinancialIncyteJakafiJakaviNovartisOncologyPricing

Denmark’s Forward Pharma plans IPO

Denmark’s Forward Pharma plans IPO

02-10-2014

Denmark-based Forward Pharma A/S today announced it has commenced an underwritten initial public offering…

BiotechnologyDenmarkFinancialForward PharmaImmunologicals

Adaptimmune completes $104 million round of financing to advance cancer therapies

Adaptimmune completes $104 million round of financing to advance cancer therapies

25-09-2014

Adaptimmune, a UK biotech company focused on using T-cell therapy to treat cancer and infectious disease,…

AdaptimmuneBiotechnologyFinancialGlaxoSmithKlineOncologyUK

Nanobiotix expands into USA with office in Boston life sciences cluster

Nanobiotix expands into USA with office in Boston life sciences cluster

22-09-2014

France-based Nanobiotix, a clinical-stage nanomedicine company pioneering novel approaches for the local…

BiotechnologyFinancialFranceNanobiotixOncologySanofiUSA

Australian government announces funding available for Soliris

18-09-2014

The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended to the Australian government that…

Alexion PharmaceuticalsAustraliaBiotechnologyFinancialPricingRare diseasesSoliris

1 to 25 of 440 results

Back to top